Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
58 hedge funds and large institutions have $17.8M invested in Oncternal Therapeutics, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 16 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
3% less call options, than puts
Call options by funds: $1.71M | Put options by funds: $1.77M
8% less funds holding
Funds holding: 63 → 58 (-5)
9.08% less ownership
Funds ownership: 23.09% → 14.01% (-9.1%)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
81% less capital invested
Capital invested by funds: $96.3M → $17.8M (-$78.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.53M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$726K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$682K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$537K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$11.2M |
| 2 |
PC
PointState Capital
New York
|
-$9.9M |
| 3 |
CII
CR Intrinsic Investors
Stamford,
Connecticut
|
-$3.18M |
| 4 |
VAM
Visium Asset Management
New York
|
-$3.1M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.48M |
ONCT Hedge Fund Activity: Q3 2013 in Review
58 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2013, worth a combined $17.8M — down 81% from $96.3M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ONCT and 13 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 19 added.
The largest buyer was AQR Capital Management, adding an estimated $1.53M. The largest seller was Oracle Investment Management, cutting an estimated $11.2M.
- 58 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2013, down from 63 in Q2 2013.
- Funds reported $17.8M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2013, down 81% quarter-over-quarter.
- 13 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2013 and 16 closed out, a net change of -3 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2013 was AQR Capital Management, an estimated $1.53M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2013 was Oracle Investment Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q3 2013.